Lantheus To Sell Springfield Plant — PharmaLogic Will Make Its Newly Approved Treatment

Agilera will supply lutetium Lu 177 dotatate under a planned long-term agreement as Lantheus awaits its own sale to Curium.

Share
Lantheus To Sell Springfield Plant — PharmaLogic Will Make Its Newly Approved Treatment

Lantheus Holdings, which makes radioactive drugs used mainly to image and track disease, agreed Sunday to sell its manufacturing business and Springfield, New Jersey, plant to PharmaLogic. The deal separates ownership of the operation from production of a Lantheus treatment: PharmaLogic's Agilera business will make the drug under a planned long-term supply agreement, according to an SEC filing Monday.

A Plant Sale With Continued Supply

The sale covers Lantheus' contract drug-development and manufacturing operation as well as the Springfield facility. Agilera, PharmaLogic's therapeutic contract-manufacturing business, will produce lutetium Lu 177 dotatate for Lantheus.

That treatment, marketed as BRAVNETSA, received final FDA approval, Lantheus said in Thursday's results announcement. The planned supply arrangement keeps the company connected to the operation it has agreed to sell.

PharmaLogic said Springfield employees will move to Agilera when the transaction closes.

Curium's Pending Purchase Of Lantheus

Lantheus is also awaiting a change in its own ownership. Under an agreement signed August 3, 2026, Curium will pay $102.50 per share in cash, with further payments dependent on commercial milestones.

Lantheus suspended its full-year financial forecast in connection with that pending acquisition. The manufacturing sale and Curium's purchase both remain pending.

Imaging Drugs Remain The Core Business

Lantheus' oncology products include Pylarify, an agent used in prostate-cancer PET scans. Its diagnostics portfolio includes Definity, which improves heart ultrasound images, and Neuraceq, an agent used in Alzheimer's disease PET scans.

Contract manufacturing sits within the company's Strategic Partnerships and Other Revenue group, alongside imaging software, licensing, royalties and research partnerships. The operation being sold is therefore part of a business that extends beyond Lantheus' own imaging drugs.

The Massachusetts-headquartered company sells mainly to U.S. hospitals, independent imaging centers and government facilities. It also reaches customers abroad through direct sales and third-party distributors.

Lantheus will provide transition services to PharmaLogic immediately after the manufacturing sale closes.

Sources

More on Lantheus Holdings

All Lantheus Holdings (LNTH) coverage →